Type your tag names separated by a space and hit enter

Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.

Abstract

OBJECTIVE

The efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men with psychiatric disorders was tested.

METHOD

Public-sector psychiatric patients with long histories of antipsychotic treatment and presumably long-standing tardive dyskinesia were randomly assigned to receive branched-chain amino acids or placebo. Treatment frequency was three times a day, 7 days a week for 3 weeks. The efficacy measure was a frequency count of videotaped tardive dyskinesia movements.

RESULTS

A robust and highly significant difference was observed between patients who received high-dose branched-chain amino acids (222 mg/kg of body weight t.i.d.) (N=18) and those who received placebo (N=18) in the percent change in tardive dyskinesia symptoms from baseline to the end of the 3-week trial. Significant and marked differences were seen between the two groups at the >/=30% and >/=60% levels of decrease in tardive dyskinesia symptoms. No clinically significant differences were seen between the pre- and posttrial results of physical examinations and laboratory screening tests. Minimal gastrointestinal symptoms occurred during the trial. The reduction in tardive dyskinesia symptoms in the amino acids group was not related to changes in antipsychotic and glucose plasma levels. A mechanism of response related to decreased amine neurotransmitter synthesis was suggested by the significant positive correlations observed between decreases in tardive dyskinesia symptoms and decreases in aromatic amino acid plasma concentrations over the course of the trial.

CONCLUSIONS

Branched-chain amino acids constitute a novel, safe treatment for tardive dyskinesia, with a strong potential for providing significant improvement in the diseased physiognomy of the afflicted person.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Division of Movement Disorders and Molecular Psychiatry, Nathan S. Kine Institute for Psychiatric Research, Orangeburg, NY 10962, USA. marich@nki.rfmh.org

    , , , , , ,

    Source

    The American journal of psychiatry 160:6 2003 Jun pg 1117-24

    MeSH

    Adult
    Amino Acids, Aromatic
    Amino Acids, Branched-Chain
    Antipsychotic Agents
    Blood Glucose
    Drug Administration Schedule
    Dyskinesia, Drug-Induced
    Humans
    Male
    Mental Disorders
    Middle Aged
    Physical Examination
    Placebos
    Sex Factors
    Treatment Outcome
    Videotape Recording

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    12777270

    Citation

    Richardson, Mary Ann, et al. "Efficacy of the Branched-chain Amino Acids in the Treatment of Tardive Dyskinesia in Men." The American Journal of Psychiatry, vol. 160, no. 6, 2003, pp. 1117-24.
    Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry. 2003;160(6):1117-24.
    Richardson, M. A., Bevans, M. L., Read, L. L., Chao, H. M., Clelland, J. D., Suckow, R. F., ... Citrome, L. (2003). Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. The American Journal of Psychiatry, 160(6), pp. 1117-24.
    Richardson MA, et al. Efficacy of the Branched-chain Amino Acids in the Treatment of Tardive Dyskinesia in Men. Am J Psychiatry. 2003;160(6):1117-24. PubMed PMID: 12777270.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. AU - Richardson,Mary Ann, AU - Bevans,Margaret L, AU - Read,Laura L, AU - Chao,Helen M, AU - Clelland,James D, AU - Suckow,Raymond F, AU - Maher,Timothy J, AU - Citrome,Leslie, PY - 2003/6/5/pubmed PY - 2003/7/24/medline PY - 2003/6/5/entrez SP - 1117 EP - 24 JF - The American journal of psychiatry JO - Am J Psychiatry VL - 160 IS - 6 N2 - OBJECTIVE: The efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men with psychiatric disorders was tested. METHOD: Public-sector psychiatric patients with long histories of antipsychotic treatment and presumably long-standing tardive dyskinesia were randomly assigned to receive branched-chain amino acids or placebo. Treatment frequency was three times a day, 7 days a week for 3 weeks. The efficacy measure was a frequency count of videotaped tardive dyskinesia movements. RESULTS: A robust and highly significant difference was observed between patients who received high-dose branched-chain amino acids (222 mg/kg of body weight t.i.d.) (N=18) and those who received placebo (N=18) in the percent change in tardive dyskinesia symptoms from baseline to the end of the 3-week trial. Significant and marked differences were seen between the two groups at the >/=30% and >/=60% levels of decrease in tardive dyskinesia symptoms. No clinically significant differences were seen between the pre- and posttrial results of physical examinations and laboratory screening tests. Minimal gastrointestinal symptoms occurred during the trial. The reduction in tardive dyskinesia symptoms in the amino acids group was not related to changes in antipsychotic and glucose plasma levels. A mechanism of response related to decreased amine neurotransmitter synthesis was suggested by the significant positive correlations observed between decreases in tardive dyskinesia symptoms and decreases in aromatic amino acid plasma concentrations over the course of the trial. CONCLUSIONS: Branched-chain amino acids constitute a novel, safe treatment for tardive dyskinesia, with a strong potential for providing significant improvement in the diseased physiognomy of the afflicted person. SN - 0002-953X UR - https://www.unboundmedicine.com/medline/citation/12777270/full_citation L2 - https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.160.6.1117?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -